AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03083782
Drug: Apixaban alone
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single dose of 10 mg apixaban administered orally at 0H on Day 1.
Trial: NCT03083782
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily dose of 100 mg cyclosporine administered orally on Days 1 to 3.
Trial: NCT03083782
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily dose of 5 mg tacrolimus administered orally on Days 1 to 3.
Trial: NCT03083782
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single dose of 10 mg apixaban administered orally on Day 3 immediately following cyclosporine
Trial: NCT03083782
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single dose of 10 mg apixaban administered orally on Day 3 immediately following tacrolimus
Trial: NCT01278264
Drug: Ropivacaine 0.25%, 0.5 ml/kg
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Posterior approach for TAP: ultrasound guided bilateral needle insertion in the transversus abdominis plane, anterior to the quadratus lumborum muscle
Trial: NCT01278264
Drug: Ropivacaine 0.25%, 0.5 ml/kg
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcostal approach for TAP: US guided needle insertion in the transversus abdominis plane, lateral to rectus sheet
Trial: NCT02539550
Drug: PF-06266047
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06266047
Trial: NCT03950232
Drug: Etrasimod
RxNorm normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrasimod 2 mg tablet by mouth, once daily up to approximately 8 years or until marketing authorization is obtained in the participant's country, whichever comes first
Trial: NCT02332473
Drug: Ypeginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02332473
Drug: Granulocyte-macrophage colony stimulating factor
RxNorm normalized name: Recombinant human granulocyte-macrophage colony stimulating factor
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00499525
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: given IV
Trial: NCT00499525
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given orallly
Trial: NCT02526784
Drug: degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05236166
Drug: Rapid withdrawal of antiepileptic
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduction by about 20 % of initial dosage every 15 days until complete discontinuation (total withdrawal time: 60 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide
Trial: NCT05236166
Drug: Slow withdrawal of antiepileptic
RxNorm normalized name: Slow-Fe
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Slow withdrawal: reduction by about 20 % of initial dosage every 40 days, until complete discontinuation (total withdrawal time: 160 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide
Trial: NCT00131521
Drug: mucomyst
RxNorm normalized name: Mucomyst
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00131521
Drug: sodium chloride (saline)
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03394989
Drug: Fluticasone propionate/salmeterol 100/50 µg
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Test Arm: Dry powder inhaler
Trial: NCT00407719
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00951392
Drug: euglycemic hyperinsulinemic clamp
RxNorm normalized name: CLAMP
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin perfusion at 1 mU.kg-1.min-1~Glucose perfusion to maintain euglycemia at 5,0 ± 0,5 mmol/l~Blood tests
Trial: NCT00677794
Drug: Clear fluids
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear fluids only after lunch.
Trial: NCT00677794
Drug: Picosalax
RxNorm normalized name: picosulfate sodium Oral Solution [Picolax]
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two sachets the evening prior to Video Capsule Endoscopy (VCE).
Trial: NCT00677794
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two (2) litres the evening prior to Video Capsule Endoscopy (VCE).
Trial: NCT02361892
Drug: ulipristal acetate
RxNorm normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5 mg/day will be administered starting from day 1 of the cycle for two courses of 3 months each
Trial: NCT03634956
Drug: Group B. Sugammadex sodium-IONM
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Group B.the vagal nerve is detected and then 2 mg / kg of sugammadex sodium is administered to remove the muscle relaxant effect
Trial: NCT04255771
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard GC (gemcitabine and cisplatin) regimen: gemcitabine 1000-1200mg/m2 intravenous infusion on days 1 and 8, cisplatin 70mg/m2 on the second day of intravenous infusion, every 3 weeks (21-day regimen) is a cycle, A total of 3 cycles.
Trial: NCT03997864
Drug: Prazosin
RxNorm normalized name: Prazosin
DrugBank: Prazosin (DB00457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved, max dose is reached, or side effects are problematic.~Tapering Decrease prazosin 1 mg every 3 days or 3 mgs per week until off completely. Tapering will take approximately 2-3 weeks.
Trial: NCT00691392
Drug: Linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid 600 mg po daily for 16 weeks (112 doses) - over-encapsulated
Trial: NCT00691392
Drug: Microcrystalline Methylcellulose - Placebo
DrugBank: Methylcellulose (DB11228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be over-encapsulated microcrystalline methylcellulose
Trial: NCT04289779
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cabozantinib 40 mg orally daily for 3 cycles
Trial: NCT04289779
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab 1200 mg IV every 3 weeks for 3 cycles
Trial: NCT00735774
Drug: 11C-ORM-13070
RxNorm normalized name: 11C-ORM-13070
DrugBank: ORM-13070 C-11 (DB15324)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of i.v. solution
Trial: NCT03695887
Drug: Nitrous Oxide Inhalant Product
RxNorm normalized name: nitrous oxide Inhalant Product
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous Oxide Inhalant Product
Trial: NCT01928433
Drug: Finafloxacin 800 mg i.v. once daily
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infused over 60 mins \[i.v. pump\]) for at least 3 days.
Trial: NCT01928433
Drug: Finafloxacin placebo i.v. once daily
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infused over 60 mins \[i.v. pump\]) for at least 3 days.
Trial: NCT01928433
Drug: Finafloxacin 800 mg tablets once daily
RxNorm normalized name: eslicarbazepine
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as four 200 mg tablets
Trial: NCT01928433
Drug: Finafloxacin placebo tablets once daily
RxNorm normalized name: Finafloxacin
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as four tablets
Trial: NCT01928433
Drug: Ciprofloxacin 400 mg i.v. twice daily
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days
Trial: NCT01928433
Drug: Ciprofloxacin placebo i.v. twice daily
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days
Trial: NCT01928433
Drug: Ciprofloxacin 500 mg oral twice daily
RxNorm normalized name: deferiprone
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered as two 250 mg capsules.
Trial: NCT01928433
Drug: Ciprofloxacin placebo oral twice daily
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as two capsules.
Trial: NCT01624714
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: alemtuzumab 12 mg IV x 5 daily doses at baseline, alemtuzumab 12 mg IV x 3 daily doses at month 12
Trial: NCT01624714
Drug: Alemtuzumab immunotherapy
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab 60 mg over 5 days for first annual cycle, then 36 mg over 3 days for subsequent annual cycle, and as needed cycles in subsequent years.
Trial: NCT01876212
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03189732
Drug: Metformin Oral
RxNorm normalized name: metformin Oral Tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03189732
Drug: Metformin local in AT
RxNorm normalized name: AT-7519
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01913327
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01913327
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Week One, Risperidone 1 mg po qd; Week Two, 2 mg po qd; Week Three, 4 mg po qd; Week Four, 6 mg po qd; Week Five (and thereafter), 8 mg po qd.
Trial: NCT01913327
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose 200 mg once orally, versus placebo single-dose, added-on to antipsychotic medication.
Trial: NCT00575913
Drug: Alfuzosin
RxNorm normalized name: Alfuzosin
DrugBank: Alfuzosin (DB00346)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alfuzosin 10 mg One tablet per day after evening meal
Trial: NCT01132482
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the course of the study, patients will receive 4 weeks of therapy: 28 days of placebo orally t.i.d. or 28 days of days of sildenafil orally t.i.d. Dosing of sildenafil will be escalated after the first week (20 mg orally t.i.d for the first week, then subjects will take 40 mg orally t.i.d. for 3 weeks). Patients not tolerating dose escalation will be discontinued from the study.
Trial: NCT01010906
Drug: Vaniprevir 300 mg
RxNorm normalized name: Vaniprevir
DrugBank: Vaniprevir (DB11929)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: single dose administration of 300 mg oral tablet
Trial: NCT01010906
Drug: Vaniprevir 200 mg
RxNorm normalized name: Vaniprevir
DrugBank: Vaniprevir (DB11929)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: single dose administration of 200 mg oral tablet
Trial: NCT03928847
Drug: Epigallocatechin-3-gallate (EGCG)
RxNorm normalized name: Epigallocatechin-3-gallate
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epigallocatechin-3-gallate (EGCG) capsules
Trial: NCT01763424
Drug: Calcipotriol
RxNorm normalized name: Calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
Trial: NCT03725007
Drug: Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib is administered as an oral solution or tablet as described in protocol.
Trial: NCT00048295
Drug: Alicaforsen
RxNorm normalized name: Alicaforsen
DrugBank: Alicaforsen (DB06224)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04409834
Drug: Enoxaparin 1 mg/kg
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 1 mg/kg administered subcutaneously (SC) every 12 hours
Trial: NCT04409834
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel 300 mg administered once orally on the day of randomization, followed by 75 mg administered once daily orally on subsequent days
Trial: NCT04409834
Drug: Enoxaparin 40 mg SC
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg administered subcutaneously (SC) once daily (reduce to 30 mg if CrCl\<30 ml/min)
Trial: NCT03341676
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 3.3 mg/mL solution for injection
Trial: NCT00003156
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03829592
Drug: misoprostol in a neutral media
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: giving misoprostol in a neutral media
Trial: NCT03829592
Drug: misoprostol in an acidic media
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: giving misoprostol in an acidic media
Trial: NCT03829592
Drug: misoprostol in an alkaline media
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: giving misoprostol in an alkaline media
Trial: NCT00769054
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local Infiltration Analgesia with 1 % Ropivacaine
Trial: NCT02292537
Drug: Nusinersen
RxNorm normalized name: Nusinersen
DrugBank: Nusinersen (DB13161)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by intrathecal (IT) lumbar puncture (LP) injection
Trial: NCT01400009
Drug: Vitamin D (Cholecalciferol )
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10,000 IU tablets. 50,000 initial dose, followed by weekly doses of 10,000 IU
Trial: NCT04055753
Drug: Doxil
RxNorm normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxil 50 mg/m2, as per institutional standard
Trial: NCT02296476
Drug: Birabresib
RxNorm normalized name: Birabresib
DrugBank: Birabresib (DB15189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally in a fasted state once daily.
Trial: NCT00445094
Drug: MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days
DrugBank: Cilastatin (DB01597)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00445094
Drug: Comparator: vancomycin / Duration of Treatment: 3 Days
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02722408
Drug: Gemcabene
RxNorm normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg tablet orally once daily for four weeks followed by 600 mg tablet orally once daily for four weeks followed by 900 mg tablet orally once daily for four weeks.
Trial: NCT03344341
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose of dapagliflozin is 5 mg once daily, taken orally in the morning, before or after breakfast. From the third week,the dose can be increased to 10 mg once daily, and last to the end of the study.
Trial: NCT03344341
Drug: Acarbose
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose was started from 50 mg once a day at dinner during the first week and titrated up to 50 mg twice a day at lunch and dinner in the second week, 50 mg three times a day at three meals in the third week, and 100 mg three times a day till the end of the study.
Trial: NCT03313414
Drug: Sofosbuvir/Velpatasvir Treatment for 14 days
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 14 day therapy with Sofosbuvir/Velpatasvir
Trial: NCT00563758
Drug: tegaserod
RxNorm normalized name: Tegaserod
DrugBank: Tegaserod (DB01079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00457392
Drug: erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
Trial: NCT03790839
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin (Januvia® 100 mg tablets for oral administration)
Trial: NCT00457392
Drug: sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib 37.5 mg daily by oral capsules in a continuous regimen
Trial: NCT03991910
Drug: Ramipril 5Mg Oral Capsule
RxNorm normalized name: Ramipril 5mg Oral capsule
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the treatment group will be given each Ramipril 2,5 mg inside a capsule as an initial dose, for 2 weeks. If there is no serious adverse effect in the observation period of 2 weeks, Ramipril 5 mg inside a capsule will be given for the next weeks until 5 days before the mitral valve surgery date. Study participant won't be able to know the drug and doses inside the capsule (for masking)
Trial: NCT04485845
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: to compare the effect of both metformin and vildagliptin on the progression of diabetes and metabolic complications and risk factors
Trial: NCT04485845
Drug: Captopril Tablets
RxNorm normalized name: Captopril Tablets
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: used to treat hypertension in metabolic syndrome patients and as a renal protector
Trial: NCT04485845
Drug: MetFORMIN 500 Mg Oral Tablet
RxNorm normalized name: metFORMIN 500 mg oral tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: antihyperglycemic drug for elevated plasma glucose level and help in weight loss for patients suffering from diabetes or metabolic syndrome
Trial: NCT03790839
Drug: Dorzagliatin
RxNorm normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucokinase activator currently under development
Trial: NCT04352855
Drug: Ceftolozane/tazobactam
RxNorm normalized name: CEFTOLOZANE/TAZOBACTAM
DrugBank: Tazobactam (DB01606)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration
Trial: NCT00696033
Drug: Diazepam
RxNorm normalized name: Diazepam
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazépam drug (0,3 mg/kg) on a single oral intake
Trial: NCT00696033
Drug: Lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lorazépam drug (0,038 mg/kg) on a single oral intake
Trial: NCT04263844
Drug: Intranasal dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: subject will receive premedication with intranasal dexmedetomidine thirty minutes before induction
Trial: NCT04263844
Drug: Intranasal Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: subject will receive premedication with intranasal midazolam thirty minutes before induction
Trial: NCT03795649
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imunomodulatory effect
Trial: NCT04457986
Drug: Erector spina plane block (ESP)
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will receive ultrasound guided regional anesthesia with bupivacaine and intravenous patient controlled analgesia with tramadol
Trial: NCT04457986
Drug: Modified thoracolumbar interfacial plane block (MTI)
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will receive ultrasound guided regional anesthesia with bupivacaine and intravenous patient controlled analgesia with tramadol
Trial: NCT03853044
Drug: Chidamide
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Chidamide 20mg per day administered orally on Day 1, 4, 8, 11 of each 21-day cycle for 6 cycles